Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress

Active Biotech (NASDAQ:ACTI) today announces that the collaboration partner Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present data on laquinimod, an investigational therapy being evaluated in relapsing and progressive forms of MS, at the 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress in Barcelona, October 7-10, 2015.

For further information, please see www.tevapharm.com.

About Laquinimod

Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of relapsing-remitting MS (RRMS), progressive MS and Huntington's disease. The global, Phase III, clinical development program evaluating laquinimod in MS includes two completed pivotal studies, ALLEGRO and BRAVO (both 0.6mg/day). A third Phase III trial, CONCERTO, is currently ongoing and evaluating two doses of laquinimod (0.6mg and 1.2mg/day) in 2,199 patients for up to 24 months. The primary outcome measure is time to three-month confirmed-disability progression as measured by the Expanded Disability Status Scale (EDSS).

For further information, please contact: Tomas Leanderson, President & CEO Tel [phone] Email: [e-mail]

Hans Kolam, CFO Tel [phone] Email: [e-mail]

Active Biotech AB (publ) (Nasdaq Stockholm:ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal phase III development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in phase II development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are ongoing for the projects ISI, ANYARA and paquinimod. Please visit www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: [phone] Fax: [phone]

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act . This information was provided to the media for publication at 2:00 p .m. CEST on Oct 6, 2015.

Active Biotech's partner Teva presents data on laquinimod http://hugin.info/1002/R/1956964/712899.pdf

HUG#1956964